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minimize side effects, and can be planned relatively 
quickly. Delaying the start of radiotherapy because 
of a complicated treatment planning process does not 
make sense. For patients requiring palliative radio-
therapy, specialized clinics have even been developed 
where treatment (with one or a few fractions of radio-
therapy) is planned and administered on the same day 
that the consultation takes place 15. Usually, fluoro-
scopic simulation and simple treatment approaches 
such as direct fields or parallel opposed fields are used 
in these clinics. However, are we utilizing the available 
radiotherapy scanning, planning, and treatment tools 
to the fullest extent possible in the palliative setting?
We believe that, in certain situations, it is possible 
to use state-of-the-art ig-i m r t  approaches to deliver 
palliative radiotherapy in a safe, efficient, and effec-
tive manner without excessive wait times. It seems 
intuitive that, if radiotherapy could be focused more 
precisely, then it could be more effective and should 
lead to fewer side effects, because the tumour can be 
targeted more accurately and normal structures can 
be avoided. In the palliative setting, in which the goal 
tends to be delivery of low-to-moderate doses of ra-
diation with minimal toxicity 13, an ig-i m r t  approach 
would seem to be most appropriate. Here, we review 
our experience using ig-i m r t  on our helical Tomo-
Therapy unit (TomoTherapy Incorporated, Madison, 
WI, U.S.A.) in the palliative setting.
2.  PATIENTS AND METHODS
In the spring of 2005, the Ottawa Hospital Cancer 
Centre installed a helical TomoTherapy unit (h t u ), 
and after a commissioning process that took 2 weeks, 
it started treating patients in September 2005. The 
h t u  was acquired mainly for research purposes, and 
many of the patients were on study protocols. How-
ever, having quickly realized the value and versatil-
ity of an ig-i m r t  approach, we began using it for 
selected palliative situations in which standard ap-
proaches might not be safe, and for unique situations 
in which palliative radiotherapy, although effective, 
would be difficult to administer. We subsequently 
created a protocol for scanning, planning, and treating 
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1.  INTRODUCTION
Radiotherapy, an essential part of the management 
of cancer patients, is used in both the curative and 
the palliative setting 1,2. Significant advances have 
been made in technology since radiation was first 
used to treat cancers more than a century ago 3. The 
most dramatic advances have occurred since the end 
of the 1980s: New imaging modalities for treatment 
planning have included computed tomography (c t ), 
magnetic resonance imaging, and positron-emission 
tomography; and sophisticated planning approaches 
such as intensity-modulated radiation therapy 
(i m r t ) 3–5 are possible. New image-guided (ig) and 
adaptive radiotherapy techniques are also emerging as 
feasible approaches to make radiotherapy more pre-
cise and effective 6,7. However, much of the literature 
for these modern, sophisticated techniques involves 
high-dose radiotherapy with curative intent 5,6,8–11.
Much less has been published about utilizing 
these advanced technologies in the setting of short-
course palliative radiotherapy 8,12. In fact, it is often 
noted that relatively simple techniques are already 
very effective 13,14, and one of the priorities has been 
to get treatment started quickly. Because days to weeks 
may be required to attain the full symptom improve-
ment benefits from palliative radiotherapy, it makes 
sense to use whichever approach can be effective, can IG-IMRT FOR PALLIATION
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in one setting patients who require urgent palliative 
radiotherapy for symptom relief 16. Here, we describe 
our experience using ig-i m r t  in the setting of short-
course palliative radiotherapy with the h t u  during the 
first 2 years of full operation. The intent of treat-
ment—as well as the treatment details, including dose 
and fractionation—was recorded electronically. The 
data were collected in an Excel spreadsheet (Micro-
soft Corporation, Redmond, WA, U.S.A.) and subse-
quently analyzed.
3.  RESULTS
In 2005, just 25 patients were treated on the h t u  as 
the staff became familiar with the equipment and the 
new processes involved in planning and treatment. 
However, during the 2-year period from January 
2006 to December 2007, a total of 227 patients were 
treated and, in 57 cases (25%), the intent was listed 
as palliative. Symptomatic bone and brain metastases 
were the most common indications for treatment 
(40% and 19% respectively). Approximately 90% of 
these palliative radiotherapy courses consisted of 10 
or fewer fractions, and the median dose was 2000 cGy 
in 5 fractions over 1 week. The number of patients 
undergoing palliative radiotherapy with ig-i m r t  
increased from 19 in 2006 to 38 in 2007. Those num-
bers represented approximately 0.8% and 1.7%, dur-
ing 2006 and 2007 respectively, of the total palliative 
radiotherapy courses given at our centre (almost half 
of the total radiotherapy courses administered annu-
ally are for palliation).
We have used ig-i m r t  for palliation in several 
types of scenarios, as outlined in the next few para-
graphs. Initially, patients with complicated and 
symptomatic metastatic or locally advanced disease 
were so treated, because treatment with conventional 
approaches would not allow delivery of adequate 
radiation doses to the planning target volume (p t v) in 
combination with sparing of normal tissues. Figure 1 
shows examples, including dosimetry, of particularly 
useful indications for ig-i m r t .
The first type of situation [Figure 1(A)] involves 
tumour volumes that are very large and adjacent to 
normal structures. Here, the tumour can be treated 
with considerable normal-tissue sparing because, 
with image guidance, small margins (0.5–1.0 cm) are 
feasible, and i m r t  allows for “dose painting,” in which 
adequate p t v coverage is combined with avoidance 
of large volumes of normal tissue. We have used this 
approach for bulky abdominopelvic recurrence of 
colorectal carcinoma and for extensive mesothelioma 
f i g u r e  1 (A) Distribution for large recurrent colon cancer being treated with abdominopelvic radiation with sparing of the liver and right 
kidney. (B) Whole-brain radiation with concurrent boost to area of gross recurrence. (C) Re-irradiation of vertebral body with relative 
sparing of spinal cord.
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involving the thorax and abdomen. In these types 
of cases, acute toxicity is quite manageable and not 
prohibitive, even with hypofractionated palliative 
radiotherapy regimens (2000 cGy in 5 fractions over 
1 week, or 3000 cGy in 10 fractions over 2 weeks).
The second type of situation [Figure 1(B)] involves 
cases in which we can boost certain areas of the p t v to 
higher doses. Traditionally, we would use two phases, 
but with ig-i m r t , we can perform a concurrent boost 
with very good dose gradients. This technique is not 
more time-consuming in terms of planning or more 
resource-intensive than is a conventional approach, but 
it is far more convenient for patients. For example, we 
believe that it is well suited for limited brain metastases, 
in which we can deliver the standard dose of 3000 cGy 
in 10 fractions over 2 weeks to the whole brain and 
simultaneously boost the areas of gross disease to a 
further 10–15 Gy. We have found that the planning for 
this treatment is simpler than performing whole-brain 
irradiation followed by a stereotactic boost.
The third type of situation [Figure 1(C)] deals 
with re-irradiation, especially when critical structures 
such as the spinal cord are involved. Here, we use 
immobilization, very small margins, and stringent 
dose–volume constraints to treat the tumour and to 
obtain maximal normal-tissue sparing. This approach 
has been used at our centre for re-treating painful bony 
vertebral metastases where the dose received by the 
spinal cord must be limited. We have been able to 
re-treat vertebrae to 3000 cGy in 10 fractions over 
2 weeks, with the cord getting only 30%–50% of the 
prescribed dose (which would keep exposure levels 
well within acceptable tolerances).
Finally, we also piloted a protocol in which pa-
tients undergo megavoltage c t  image acquisition, 
target delineation, i m r t  treatment planning, and 
verification of position before treatment, and finally 
delivery of the first fraction of radiation all in one 
visit (full details published elsewhere 16). Subse-
quently, we also developed a protocol called Tomo-
p a l  (TomoTherapy—Planning and Administration 
Linked), during which we scan, plan, and deliver 
single-fraction treatment all in one session for patients 
requiring urgent radiotherapy. The approach is similar 
to that used in our rapid palliative radiotherapy clinic, 
designed for rapid access to single-fraction treatment 
especially suited for treating bone metastases. The key 
advantage of Tomo-p a l  is that we are able to scan, 
plan, and treat patients in approximately 1 hour, which 
is extremely convenient for patients and also has the 
potential to reduce toxicity (both acute and late).
Comparisons of the quick i m r t  plans with stan-
dard dosimetry using simple direct or parallel fields 
demonstrate much more homogeneous doses to the 
target volumes, reduced hotspot areas, and much 
lower doses to adjacent normal tissues (Figure 2). At 
our centre, with clinical mark-ups or fluoroscopic 
simulation, we have traditionally used 1.5–2.5 cm 
margins around areas of disease when delivering 
palliative radiotherapy. With an ig-i m r t  approach, we 
perform volumetric planning to reduce the irradiated 
volume, and we tend to use smaller margins, ranging 
from 0.5 cm to 1.0 cm. We have gained confidence 
in the use of such small margins because of the veri-
fication imaging for patient position and target local-
ization before each fraction of radiotherapy is 
delivered. The delivery quality assurance measure-
ments also show good agreement between planned 
and delivered dose. The i m r t  plans also tend to be 
better than our three-dimensional treatment plans 
because of the ability to tailor the radiotherapy to 
various unusual tumour geometries and because of 
the smaller margins that can be used. Given the lim-
ited follow-up thus far, no significant complications 
have been noted in the short term in our treated pa-
tients. The approach discussed here has been used 
most often for painful bone metastases, including 
single-fraction treatment.
4.  DISCUSSION
Palliative radiotherapy forms a very large proportion 
of the workload at cancer centres 13,17,18, and our data 
are consistent with those findings. However, palliative 
radiotherapy usually does not require the same propor-
tion of resources 13–15,19, largely because even simple 
palliative radiotherapy techniques can be very effective 
and lead to high rates of symptom improvement 13,14. In 
certain situations, though, modern radiotherapy tech-
nology needs to extend to the palliative setting when 
appropriate. Studies have already demonstrated that c t -
based imaging and planning of palliative radiotherapy 
is superior to that with conventional approaches that 
use clinical mark-ups or fluoroscopy 20–22, and using 
ig-i m r t  for palliation is a natural extension.
When using ig-i m r t , we can more confidently 
use relatively small margins (0.5–1.0 cm) around the 
areas of tumour, because patients will be re-imaged 
for verification of position and tumour location be-
fore each treatment. We have been impressed by the 
reproducibility of patient set-ups and the minimal 
shifts required. The distributions achieved also de-
liver a much more homogeneous dose to the p t v and 
minimize dose to the adjacent normal tissues, even 
with a rapid i m r t  planning process.
Based on our experience, the four main scenarios 
in which we have found ig-i m r t  to be most useful 
are these:
Tumours that are large and that have complex  • 
geometric configurations are difficult to treat 
with conventional approaches, especially when 
adjacent to critical structures. For this type of 
treatment, we use a standard planning c t for im-
age acquisition. Fairly complex planning is then 
performed. Although this planning can be labour-
intensive, it can allow for radiotherapy to areas 
traditionally considered too large or too difficult to IG-IMRT FOR PALLIATION
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treat. This approach is appropriate when patients 
have symptomatic disease not responding to other 
approaches.
A region is being treated, but a certain portion  • 
should be boosted to a higher dose. This situation 
occurs most often with limited brain metastases, 
in which we can use our ig-i m r t  equipment to 
deliver standard whole-brain radiation doses 
with a concurrent boost to the areas of gross 
disease. This approach tends to be simpler than 
whole-brain radiation followed by subsequent 
stereotactic radiotherapy. The planning is no more 
difficult, and the approach is obviously more 
convenient for patients.
Re-irradiation to certain areas to treat the tumour  • 
(which likely responded well to previous radio-
therapy) and the dominant area of symptomatic 
progression. In this scenario, minimizing radio-
therapy dose to structures such as the spinal cord 
is important. Reports have been published about 
the value of i m r t  for spinal and paraspinal tu-
mours 11,12. Again, a standard planning c t  is re-
quired, as is complex i m r t  planning, but we have 
not found this work to be much more onerous 
than complex planning using a three-dimensional 
conformal approach.
In our streamlined process,  •  ig-i m r t  has proved 
extremely useful for scanning, planning, and 
treating patients all in one session. In this ap-
proach, all procedures can be carried out safely 
and efficiently with the patient remaining on the 
treatment couch in one room during the entire 
time. These cases—for example, painful bone 
metastases—usually have less complicated 
planning, but the treatment distributions are still 
far superior to those that can be achieved using 
standard approaches. And we can achieve these 
superior results in the same time, or less, than it 
would take to treat the patient with simpler radio-
therapy techniques. Multiple targets can also be 
effectively treated using this approach.
Our experience suggests that the scope of pallia-
tive radiotherapy will expand in the future if we start 
to embrace and utilize these ig-i m r t  technologies in 
the appropriate settings. In situations in which we 
may previously have thought that the size of the tu-
mour, its anatomic location, or its geometry precludes 
f i g u r e  2 (A) Treatment of sacrum with image-guided intensity-modulated radiation therapy (ig-i m r t ) as compared with traditional fields, 
showing significant reduction of high-dose region and hotspots. (B) Treatment of two adjacent sites of vertebral body metastases with 
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the use of radiotherapy, i m r t  has the potential to 
change that thinking, especially if image guidance, 
which can reduce margins around the tumour and 
radiotherapy dose adjacent normal tissues, is also 
incorporated. The ig-i m r t  technique also offers more 
opportunities for safe re-irradiation to previously 
treated sites. And in many situations, ig-i m r t  can be 
as fast and efficient as simpler approaches, yet the 
delivery of the radiotherapy will be more conformal. 
With experience, i m r t  treatment planning can be 
streamlined and carried out relatively quickly for 
many common situations. We have also been able to 
redesign some our processes to make sure that patients 
requiring urgent palliative radiotherapy can be 
treated just as rapidly with ig-i m r t  as they can be with 
a Cobalt-60 unit or a linear accelerator.
Our results indicate mainly the feasibility of 
ig-i m r t  for palliative situations; however, clinical 
results with more relevant patient outcomes should 
be forthcoming as more centres embrace this ap-
proach. But there is no reason to believe that this 
approach cannot be at least as effective as traditional 
palliative radiotherapy treatment, in which clinically 
meaningful symptom improvement is documented in 
60%–80% of patients 13,23.
So far, we have not had any concerns whatsoever 
about the safety of the approach, and substantial lit-
erature has already been published with regard to the 
use of i m r t  in the curative and adjuvant settings. In 
general, our patients treated palliatively with ig-i m r t  
appear very happy to undergo such an efficient process. 
We look forward to seeing more cancer centres publish-
ing their results with ig-i m r t  for palliation.
5.  CONCLUSIONS
In the palliative setting, ig-i m r t  is feasible and efficient, 
and offers a broad range of options for patients with 
symptomatic cancer not responding to other therapies. 
Although ig-i m r t  is certainly not necessary for all 
patients requiring palliative radiotherapy, in specific 
situations it may be the most appropriate approach. Its 
future holds great promise for patients with advanced 
cancer who could benefit from radiotherapy.
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